A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Perinatal Tissue Mesenchyme Stem Cells in the ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2016-2018

ABSTRACT

The study is to investigate the efficacy and safety of perinatal tissue mesenchyme stem cells treatment on the appearance of a caesarean scar as compared to a similar untreated scar. Detailed Description Nowadays, cesarean is one of the most common surgical interventions and its prevalence has increased in most countries in the recent years. Delay in healing of cesarean wound and formation of visible scar are common symptoms of maternal morbidity after cesarean section. These complications affect mother's quality of life due to stress, anxiety, delay in mother's ability and health recovery, and also they are associated with additional cost as a result of the increased need for wide spectrum antibiotics and sometimes hospitalization and repeated repair of wound. Improve the final aspect of would and visible scars, have been a challenge for medicine. Mesenchymal stem cells (MSC) are a population of pluripotent stem cells that are self-renewing and capable of differentiating into canonical cells of the mesenchyme. Recently, stem cells have been applied to regenerative medicine, even for internal organs such as blood vessels, nerves, and heart. The study is to investigate the efficacy and safety of perinatal tissue mesenchyme stem cells treatment on the appearance of a caesarean scar as compared to a similar untreated scar. This is a randomized, double-blind, placebo-controlled clinical trial designed to investigate the efficacy and safety of perinatal tissue mesenchyme stem cells (MSC) treatment on the appearance of a caesarean scar as compared to a similar untreated scar. A total of ninety (90) participants will be randomized (1:1:1) to receive MSC or placebo. All of participants will be undergoing delivery by lower segment caesarean section through a transverse abdominal incision, and there will be no clear indication for a particular surgical technique or material to be used. In low-dose MSC group, participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days; In high-dose MSC group, participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days; And in placebo group, participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days. After randomization, baseline data, and transdermal treatment, participants will be followed up at 1 month, 3 months and 6 months. For the purpose of the endpoint analysis and safety evaluations, the investigators will utilize an "intention-to-treat" study population. More... »

URL

https://clinicaltrials.gov/show/NCT02772289

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The study is to investigate the efficacy and safety of perinatal tissue mesenchyme stem cells treatment on the appearance of a caesarean scar as compared to a similar untreated scar.\n\nDetailed Description\nNowadays, cesarean is one of the most common surgical interventions and its prevalence has increased in most countries in the recent years. Delay in healing of cesarean wound and formation of visible scar are common symptoms of maternal morbidity after cesarean section. These complications affect mother's quality of life due to stress, anxiety, delay in mother's ability and health recovery, and also they are associated with additional cost as a result of the increased need for wide spectrum antibiotics and sometimes hospitalization and repeated repair of wound. Improve the final aspect of would and visible scars, have been a challenge for medicine. Mesenchymal stem cells (MSC) are a population of pluripotent stem cells that are self-renewing and capable of differentiating into canonical cells of the mesenchyme. Recently, stem cells have been applied to regenerative medicine, even for internal organs such as blood vessels, nerves, and heart. The study is to investigate the efficacy and safety of perinatal tissue mesenchyme stem cells treatment on the appearance of a caesarean scar as compared to a similar untreated scar. This is a randomized, double-blind, placebo-controlled clinical trial designed to investigate the efficacy and safety of perinatal tissue mesenchyme stem cells (MSC) treatment on the appearance of a caesarean scar as compared to a similar untreated scar. A total of ninety (90) participants will be randomized (1:1:1) to receive MSC or placebo. All of participants will be undergoing delivery by lower segment caesarean section through a transverse abdominal incision, and there will be no clear indication for a particular surgical technique or material to be used. In low-dose MSC group, participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days; In high-dose MSC group, participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days; And in placebo group, participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days. After randomization, baseline data, and transdermal treatment, participants will be followed up at 1 month, 3 months and 6 months. For the purpose of the endpoint analysis and safety evaluations, the investigators will utilize an \"intention-to-treat\" study population.", 
    "endDate": "2018-11-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02772289", 
    "keywords": [
      "Phase II", 
      "Double-Blind", 
      "efficacy", 
      "safety", 
      "stem cell", 
      "caesarean", 
      "stem cell treatment", 
      "appearance", 
      "cesarean", 
      "surgical intervention", 
      "prevalence", 
      "country", 
      "delay", 
      "healing", 
      "common symptom", 
      "maternal morbidity", 
      "Cesarean Section", 
      "complication", 
      "mother", 
      "life", 
      "stress", 
      "anxiety", 
      "recovery", 
      "additional cost", 
      "increased need", 
      "wide spectrum", 
      "hospitalization", 
      "repair", 
      "Wound and Injury", 
      "Improve", 
      "final aspect", 
      "challenge", 
      "medicine", 
      "Mesenchymal Stromal Cell", 
      "population", 
      "pluripotent stem cell", 
      "cell", 
      "Mesoderm", 
      "regenerative medicine", 
      "internal organ", 
      "blood vessel", 
      "nerve", 
      "heart", 
      "placebo-controlled clinical trial", 
      "ninety", 
      "placebo", 
      "delivery", 
      "transverse", 
      "clear indication", 
      "surgical technique", 
      "cell group", 
      "dose", 
      "gel", 
      "placebo group", 
      "Random Allocation", 
      "baseline data", 
      "endpoint", 
      "safety evaluation", 
      "study population"
    ], 
    "name": "A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02772289"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00021.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.490274.c", 
        "type": "Organization"
      }
    ], 
    "startDate": "2016-05-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/s13063-018-2478-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101318561", 
          "https://doi.org/10.1186/s13063-018-2478-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13063-018-2478-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101318561", 
          "https://doi.org/10.1186/s13063-018-2478-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02772289"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02772289'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02772289'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02772289'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02772289'


 

This table displays all metadata directly associated to this object as RDF triples.

82 TRIPLES      16 PREDICATES      75 URIs      68 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02772289 schema:about anzsrc-for:3053
2 schema:description The study is to investigate the efficacy and safety of perinatal tissue mesenchyme stem cells treatment on the appearance of a caesarean scar as compared to a similar untreated scar. Detailed Description Nowadays, cesarean is one of the most common surgical interventions and its prevalence has increased in most countries in the recent years. Delay in healing of cesarean wound and formation of visible scar are common symptoms of maternal morbidity after cesarean section. These complications affect mother's quality of life due to stress, anxiety, delay in mother's ability and health recovery, and also they are associated with additional cost as a result of the increased need for wide spectrum antibiotics and sometimes hospitalization and repeated repair of wound. Improve the final aspect of would and visible scars, have been a challenge for medicine. Mesenchymal stem cells (MSC) are a population of pluripotent stem cells that are self-renewing and capable of differentiating into canonical cells of the mesenchyme. Recently, stem cells have been applied to regenerative medicine, even for internal organs such as blood vessels, nerves, and heart. The study is to investigate the efficacy and safety of perinatal tissue mesenchyme stem cells treatment on the appearance of a caesarean scar as compared to a similar untreated scar. This is a randomized, double-blind, placebo-controlled clinical trial designed to investigate the efficacy and safety of perinatal tissue mesenchyme stem cells (MSC) treatment on the appearance of a caesarean scar as compared to a similar untreated scar. A total of ninety (90) participants will be randomized (1:1:1) to receive MSC or placebo. All of participants will be undergoing delivery by lower segment caesarean section through a transverse abdominal incision, and there will be no clear indication for a particular surgical technique or material to be used. In low-dose MSC group, participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days; In high-dose MSC group, participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days; And in placebo group, participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days. After randomization, baseline data, and transdermal treatment, participants will be followed up at 1 month, 3 months and 6 months. For the purpose of the endpoint analysis and safety evaluations, the investigators will utilize an "intention-to-treat" study population.
3 schema:endDate 2018-11-01T00:00:00Z
4 schema:keywords Cesarean Section
5 Double-Blind
6 Improve
7 Mesenchymal Stromal Cell
8 Mesoderm
9 Phase II
10 Random Allocation
11 Wound and Injury
12 additional cost
13 anxiety
14 appearance
15 baseline data
16 blood vessel
17 caesarean
18 cell
19 cell group
20 cesarean
21 challenge
22 clear indication
23 common symptom
24 complication
25 country
26 delay
27 delivery
28 dose
29 efficacy
30 endpoint
31 final aspect
32 gel
33 healing
34 heart
35 hospitalization
36 increased need
37 internal organ
38 life
39 maternal morbidity
40 medicine
41 mother
42 nerve
43 ninety
44 placebo
45 placebo group
46 placebo-controlled clinical trial
47 pluripotent stem cell
48 population
49 prevalence
50 recovery
51 regenerative medicine
52 repair
53 safety
54 safety evaluation
55 stem cell
56 stem cell treatment
57 stress
58 study population
59 surgical intervention
60 surgical technique
61 transverse
62 wide spectrum
63 schema:name A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars
64 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02772289
65 schema:sdDatePublished 2019-03-07T15:26
66 schema:sdLicense https://scigraph.springernature.com/explorer/license/
67 schema:sdPublisher N380b93f57b014f99b6ca3e786527e920
68 schema:sponsor https://www.grid.ac/institutes/grid.490274.c
69 schema:startDate 2016-05-01T00:00:00Z
70 schema:subjectOf sg:pub.10.1186/s13063-018-2478-x
71 schema:url https://clinicaltrials.gov/show/NCT02772289
72 sgo:license sg:explorer/license/
73 sgo:sdDataset clinical_trials
74 rdf:type schema:MedicalStudy
75 N380b93f57b014f99b6ca3e786527e920 schema:name Springer Nature - SN SciGraph project
76 rdf:type schema:Organization
77 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
78 rdf:type schema:DefinedTerm
79 sg:pub.10.1186/s13063-018-2478-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1101318561
80 https://doi.org/10.1186/s13063-018-2478-x
81 rdf:type schema:CreativeWork
82 https://www.grid.ac/institutes/grid.490274.c schema:Organization
 




Preview window. Press ESC to close (or click here)


...